ZYME

Zymeworks Inc

Add to Watchlist

Advanced Chart

11.710

+0.180(+1.560%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

11.790

Open

11.540

VWAP

11.71

Vol

333.06K

Mkt Cap

815.99M

Low

11.510

Amount

3.90M

EV/EBITDA(TTM)

Total Shares

70.70M

550.74M

EV/OCF(TTM)

P/S(TTM)

9.48

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

16.99M

-11.72%

-0.453

-7.65%

31.40M

+96.27%

-0.357

-8.33%

29.56M

-4.73%

-0.385

+24.19%

Estimates Revision

The market is revising Upward the revenue expectations for Zymeworks Inc. (ZYME) for FY2025, with the revenue forecasts being adjusted by 42.4% over the past three months. During the same period, the stock price has changed by -20.18%.

Revenue Estimates for FY2025

Revise Upward

+42.4%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-31.7%

In Past 3 Month

Stock Price

Go Down

-20.18%

In Past 3 Month

9 Analyst Rating

87.87% Upside

Wall Street analysts forecast ZYME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYME is 22.00 USD with a low forecast of 12.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

2 Hold

0 Sell

Strong Buy

87.87% Upside

Current: 11.710

Low

12.00

Averages

22.00

High

30.00

87.87% Upside

Current: 11.710

Low

12.00

Averages

22.00

High

30.00

HC Wainwright & Co.

Robert Burns

Hold

Maintains

$12 → $13

2025-03-10

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$12 → $13

2025-03-10

Maintains

Hold

Reason

Citigroup

Yigal Nochomovitz

Strong Buy

Maintains

$18 → $19

2025-03-07

Reason

Citigroup

Yigal Nochomovitz

Price Target

$18 → $19

2025-03-07

Maintains

Strong Buy

Reason

Citi analyst Yigal Nochomovitz raised the firm's price target on Zymeworks to $19 from $18 and keeps a Buy rating on the shares.

Wells Fargo

Derek Archila

Hold

Maintains

$12 → $14

2024-12-19

Reason

Wells Fargo

Derek Archila

Price Target

$12 → $14

2024-12-19

Maintains

Hold

Reason

Wells Fargo raised the firm's price target on Zymeworks to $14 from $12 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR).

JP Morgan

Brian Cheng

Hold

Buy

Upgrades

$18

2024-12-16

Reason

JP Morgan

Brian Cheng

Price Target

$18

2024-12-16

Upgrades

Hold

Buy

Reason

HC Wainwright & Co.

Robert Burns

Hold

Reiterates

$12

2024-11-22

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$12

2024-11-22

Reiterates

Hold

Reason

Leerink Partners

Andrew Berens

Hold

Buy

Upgrades

$10 → $25

2024-11-07

Reason

Leerink Partners

Andrew Berens

Price Target

$10 → $25

2024-11-07

Upgrades

Hold

Buy

Reason

Leerink upgraded Zymeworks (ZYME) to Outperform from Market Perform with a price target of $25, up from $10, following the advancement of the wholly owned pipeline into the clinical stage setting, and ahead of the November 29th PDUFA for outlicensed zanidatimab. In 2022, Zymeworks outlicensed zanidatimab to Jazz Pharmaceuticals (JAZZ), which provided the company with non-dilutive capitalthat enabled them to overcome their precarious cash runway situation of early 2022 and reinvest in the pipeline. However, this decision tempered the investment thesis, as the remaining drugs were preclinical or had clinical hurdles, the firm notes. Leerink thinks the R&D investment has begun to materialize as the company enters the clinic with two of these programs and is close to IND for two other.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Zymeworks Inc (ZYME.O) is -9.97, compared to its 5-year average forward P/E of -3.18. For a more detailed relative valuation and DCF analysis to assess Zymeworks Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.18

Current PE

-9.97

Overvalued PE

15.14

Undervalued PE

-21.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.24

Current EV/EBITDA

-3.74

Overvalued EV/EBITDA

-1.13

Undervalued EV/EBITDA

-5.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

24.46

Current PS

7.47

Overvalued PS

55.43

Undervalued PS

-6.51

Financials

Annual

Quarterly

FY2025Q1

YoY :

+170.29%

27.11M

Total Revenue

FY2025Q1

YoY :

-32.24%

-25.61M

Operating Profit

FY2025Q1

YoY :

-28.49%

-22.64M

Net Income after Tax

FY2025Q1

YoY :

-28.57%

-0.30

EPS - Diluted

FY2025Q1

YoY :

-90.23%

-3.75M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

-44.98%

-84.09

FCF Margin - %

FY2025Q1

YoY :

-73.54%

-83.50

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

1.3M

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

25.4M

USD

Months

3-6

14.4M

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.0M

Volume

6-9

Months

0.0

Volume

0-12

Months

699.5K

Volume

Bought

0-3

692.1K

Volume

Months

3-6

1.6M

Volume

Months

6-9

0.0

Volume

Months

0-12

1.8M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

1.3M

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

25.4M

USD

Months

3-6

14.4M

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ZYME News & Events

Events Timeline

2025-05-08 (ET)

2025-05-08

17:40:20

Zymeworks reports Q1 EPS (30c), consensus (73c)

2025-04-04 (ET)

2025-04-04

08:09:42

Kalaris Therapeutics appoints Leone Patterson to board of directors

2025-03-05 (ET)

2025-03-05

16:21:34

Zymeworks reports Q 4EPS (31c), consensus (9c)

News

5.0

04-21Newsfilter

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

9.5

04-17Newsfilter

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

1.0

03-26Newsfilter

Zymeworks Announces Participation in Upcoming Investor Conferences

People Also Watch

BRDG

Bridge Investment Group Holdings Inc

Hyster-Yale Materials Handling Inc

Studio City International Holdings Ltd

FAQ

What is Zymeworks Inc (ZYME) stock price today?

The current price of ZYME is 11.71 USD — it has increased 1.56 % in the last trading day.

ZYME

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ZYME News & Events

Events Timeline

News

People Also Watch

FAQ

What is Zymeworks Inc (ZYME) stock price today?

What is Zymeworks Inc (ZYME)'s business?

What is the price predicton of ZYME Stock?

What is Zymeworks Inc (ZYME)'s revenue for the last quarter?

What is Zymeworks Inc (ZYME)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Zymeworks Inc (ZYME)'s fundamentals?

How many employees does Zymeworks Inc (ZYME). have?

What is Zymeworks Inc (ZYME) market cap?